COMMERCIAL POTENTIAL DRIVES STRONG MARKET SUPPORT FOR DRUG TREATMENT
BIOSHARES CONFERENCE
Innate Immunotherapeutics recently participated in the 12th Bioshares Biotech Summit held on Friday 29 - Saturday 30 July, 2016 in Queenstown New Zealand, with Company Managing Director & CEO Simon Wilkinson providing an update on the progress of Innate’s Phase 2B clinical trial of MIS416.
For further information please download PDF attached:
Download this document
